Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MAP Pharmaceuticals
Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.
Sanofi has paid $45m via an upfront licensing fee and equity investment in young South San Francisco-based biotech MyoKardia, which is developing targeted therapies for genetic heart disease. The collaboration is an outgrowth of Sanofi's Sunrise initiative, a partnership model focused on early stage opportunities.
Inhalable acute migraine drug previously known as Levadex receives third “complete response” letter from FDA.
For the third time, the FDA has rejected Allergan's experimental inhaled migraine drug dihydroergotamine, which has now changed its moniker from Levadex to Semprana.
- Medical Devices
- Site Specific
- Drug Delivery
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.